Multiple molecular forms of acid-stable plasmin inhibitor derived from human urinary trypsin inhibitor. 1983

H Sumi, and N Toki, and S Takasugi, and S Maehara, and H Tsushima, and K Akazawa, and H Mihara

It was found that cyanogen bromide (BrCN) treatment of the highly purified human urinary trypsin inhibitors (H-UTI; specific activity 1,897 U/mg protein, and L-UTI; specific activity 1,850 U/mg protein) readily produced new plasmin inhibitors with almost no loss of UTI activity. Five multiple forms of chemically cleaved inhibitors (UTIB-I, UTIB-II, UTIB-III, UTIB-IV and UTIB-V) could be isolated from BrCN-treated L-UTI by isoelectric focusing and gel filtration. These inhibitors were very acid-stable and their isoelectric points (pI) were 4.5, 4.6, 4.9, 5.1 and 6.4, respectively. The molecular weights by SDS-polyacrylamide gel electrophoresis were almost the same at about 23,000 +/- 3,000. Although these inhibitors showed both anti-plasmin and anti-trypsin activities, much higher anti-plasmin/anti-trypsin activities were observed in the cleaved inhibitors than in the parent UTI. They competitively inhibited human plasmin with Ki values of 3.0-4.1 X 10(-8) mol/l (H-D-Val-Leu-Lys-pNA substrate).

UI MeSH Term Description Entries
D008970 Molecular Weight The sum of the weight of all the atoms in a molecule. Molecular Weights,Weight, Molecular,Weights, Molecular
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D003488 Cyanogen Bromide Cyanogen bromide (CNBr). A compound used in molecular biology to digest some proteins and as a coupling reagent for phosphoroamidate or pyrophosphate internucleotide bonds in DNA duplexes. Bromide, Cyanogen
D004355 Drug Stability The chemical and physical integrity of a pharmaceutical product. Drug Shelf Life,Drugs Shelf Lives,Shelf Life, Drugs,Drug Stabilities,Drugs Shelf Life,Drugs Shelf Live,Life, Drugs Shelf,Shelf Life, Drug,Shelf Live, Drugs,Shelf Lives, Drugs
D004591 Electrophoresis, Polyacrylamide Gel Electrophoresis in which a polyacrylamide gel is used as the diffusion medium. Polyacrylamide Gel Electrophoresis,SDS-PAGE,Sodium Dodecyl Sulfate-PAGE,Gel Electrophoresis, Polyacrylamide,SDS PAGE,Sodium Dodecyl Sulfate PAGE,Sodium Dodecyl Sulfate-PAGEs
D006023 Glycoproteins Conjugated protein-carbohydrate compounds including MUCINS; mucoid, and AMYLOID glycoproteins. C-Glycosylated Proteins,Glycosylated Protein,Glycosylated Proteins,N-Glycosylated Proteins,O-Glycosylated Proteins,Glycoprotein,Neoglycoproteins,Protein, Glycosylated,Proteins, C-Glycosylated,Proteins, Glycosylated,Proteins, N-Glycosylated,Proteins, O-Glycosylated
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006863 Hydrogen-Ion Concentration The normality of a solution with respect to HYDROGEN ions; H+. It is related to acidity measurements in most cases by pH pH,Concentration, Hydrogen-Ion,Concentrations, Hydrogen-Ion,Hydrogen Ion Concentration,Hydrogen-Ion Concentrations
D000933 Antifibrinolytic Agents Agents that prevent fibrinolysis or lysis of a blood clot or thrombus. Several endogenous antiplasmins are known. The drugs are used to control massive hemorrhage and in other coagulation disorders. Antifibrinolysin,Antifibrinolysins,Antifibrinolytic,Antifibrinolytic Agent,Antiplasmin,Antiplasmins,Antifibrinolytics,Plasmin Inhibitor,Plasmin Inhibitors,Agent, Antifibrinolytic,Agents, Antifibrinolytic,Inhibitor, Plasmin,Inhibitors, Plasmin
D014361 Trypsin Inhibitors Serine proteinase inhibitors which inhibit trypsin. They may be endogenous or exogenous compounds. Trypsin Inhibitor,Inhibitor, Trypsin,Inhibitors, Trypsin

Related Publications

H Sumi, and N Toki, and S Takasugi, and S Maehara, and H Tsushima, and K Akazawa, and H Mihara
September 1978, Thrombosis research,
H Sumi, and N Toki, and S Takasugi, and S Maehara, and H Tsushima, and K Akazawa, and H Mihara
January 1966, Voprosy meditsinskoi khimii,
H Sumi, and N Toki, and S Takasugi, and S Maehara, and H Tsushima, and K Akazawa, and H Mihara
October 1990, Clinica chimica acta; international journal of clinical chemistry,
H Sumi, and N Toki, and S Takasugi, and S Maehara, and H Tsushima, and K Akazawa, and H Mihara
July 1988, Biochimica et biophysica acta,
H Sumi, and N Toki, and S Takasugi, and S Maehara, and H Tsushima, and K Akazawa, and H Mihara
August 1993, Biokhimiia (Moscow, Russia),
H Sumi, and N Toki, and S Takasugi, and S Maehara, and H Tsushima, and K Akazawa, and H Mihara
December 1999, Nihon rinsho. Japanese journal of clinical medicine,
H Sumi, and N Toki, and S Takasugi, and S Maehara, and H Tsushima, and K Akazawa, and H Mihara
July 2010, Nihon rinsho. Japanese journal of clinical medicine,
H Sumi, and N Toki, and S Takasugi, and S Maehara, and H Tsushima, and K Akazawa, and H Mihara
August 2005, Nihon rinsho. Japanese journal of clinical medicine,
H Sumi, and N Toki, and S Takasugi, and S Maehara, and H Tsushima, and K Akazawa, and H Mihara
July 1986, Clinica chimica acta; international journal of clinical chemistry,
H Sumi, and N Toki, and S Takasugi, and S Maehara, and H Tsushima, and K Akazawa, and H Mihara
September 1983, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology,
Copied contents to your clipboard!